DEFM14A: Genmab Offers $97/Share to Acquire Merus N.V.

Genmab A/S, through its subsidiary, has launched a tender offer to acquire all outstanding common shares of Merus N.V. for $97.00 per share in cash, with Merus's Board unanimously recommending the offer.

Summary

• Genmab Holding II B.V., a wholly-owned subsidiary of Genmab A/S, has made an offer to purchase all issued and outstanding common shares of Merus N.V. for $97.00 per share in cash.
• The Merus Board of Directors unanimously determined the offer is in the best interests of Merus and its stakeholders, recommending shareholders accept the offer and vote FOR the related proposals.
• The offer price represents a 41% premium to Merus's closing share price on September 26, 2025, and a 50% premium to the 60-day volume-weighted average price as of the same date.
• An Extraordinary General Meeting (EGM) of shareholders is scheduled for Tuesday, December 9, 2025, to vote on proposals related to the acquisition and subsequent corporate reorganization.
• If the offer is successful, Merus will become an indirect wholly-owned subsidiary of Genmab through 'Back-End Transactions,' which may involve a statutory merger or compulsory acquisition.
• Merus's common shares will be delisted from the Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934.
• Outstanding 'in-the-money' Merus stock options will vest in full at the Acceptance Time and be converted into cash based on the difference between the offer price and the exercise price.
• Genmab expects to fund the acquisition using a combination of debt financing, with up to $6.0 billion committed, and cash on hand; the offer is not conditioned on financing.
• A Merus termination fee of $240 million is payable to Genmab under certain circumstances, including if Merus accepts a superior proposal.
• A reverse termination fee of $416 million may be payable by Genmab to Merus if the transaction terminates under specified circumstances, primarily related to antitrust failures.

Sentiment

Score: 8

Explanation: The filing details a unanimous board recommendation for an all-cash acquisition at a significant premium, backed by a fairness opinion and committed financing. While there are standard risks and tax implications for non-tendering shareholders, the overall tone and terms are highly favorable for Merus shareholders, providing certainty and immediate value.

Positives

• The offer price of $97.00 per common share provides immediate liquidity and certainty of value for Merus shareholders.
• The offer represents a significant premium: 41% over the closing price on September 26, 2025, and 50% over the 60-day volume-weighted average price as of that date.
• The Merus Board unanimously recommended the offer, concluding it is in the best interests of Merus and the sustainable success of its business, considering all stakeholders.
• Genmab has secured committed debt financing of up to $6.0 billion, and the offer is not subject to a financing condition, increasing the certainty of closing.
• The transaction provides an exit for shareholders from the inherent risks of remaining a standalone biopharmaceutical company, including challenges in R&D, regulatory approvals, and commercialization.
• Merus executive officers and directors will receive the same consideration for their common shares as other shareholders.
• Outstanding 'in-the-money' Merus stock options will vest in full at the Acceptance Time and be converted into cash.
• Continuing employees will receive comparable base salary, target annual cash incentive, and employee benefits for one year following the closing.
• The Protection Foundation, which held anti-takeover rights, has agreed to support the transaction and will not exercise its call option, facilitating the acquisition.

Negatives

• Merus shareholders will not participate in any potential future upside from Merus's standalone strategic business plan or the future success of its product candidates.
• Minority shareholders who do not tender their shares may receive a lower net consideration due to a 15% Dutch dividend withholding tax in the Back-End Cancellation scenario, unless an exemption applies.
• Merus shareholders are not entitled to appraisal or dissenters' rights under Dutch law with respect to the Offer or the Back-End Transactions.
• The Transaction Agreement imposes restrictions on Merus's operations during the interim period, which could potentially delay or prevent the pursuit of certain business opportunities.
• A $240 million termination fee is payable by Merus under certain circumstances, including if Merus terminates the agreement to accept a superior proposal, which could deter alternative bidders.
• Executive officers may be subject to an excise tax under Section 4999 of the Code, although Merus has agreed to make reimbursement payments up to an aggregate cap of $9.3 million.

Risks

• The closing of the offer is conditioned upon shareholders tendering (and not properly withdrawing) a number of common shares representing at least 80% (or 75% if reduced) of Merus's issued and outstanding common shares.
• The transaction might not be consummated for an extended period or at all, due to various conditions, including the satisfaction of regulatory approvals (e.g., HSR Act, UK CMA).
• If the offer is not completed, Merus would remain an independent public company, subject to market volatility, the risks of its business plan, and would have incurred significant transaction expenses.
• The risk of litigation from shareholders or other parties challenging the Transaction Agreement or the Transactions.
• The consideration received by shareholders in the Offer and Back-End Transactions will be a taxable event for U.S. federal income tax purposes, and non-tendering shareholders may face Dutch dividend withholding tax.
• Governmental authorities with jurisdiction over antitrust matters could attempt to condition their approvals on burdensome terms or divestitures, potentially impacting the transaction.
• The inherent uncertainties and risks associated with achieving and executing Merus's business and financial plans as a standalone company, including clinical trial outcomes, regulatory approvals, and commercialization challenges.
• Challenges associated with raising additional capital as a standalone company, which could lead to potential dilution for existing shareholders.
• In a Back-End Compulsory Acquisition, the Enterprise Court will determine the price to be paid for the common shares, which may differ from the Offer Consideration.

Future Outlook

Merus management's unaudited prospective financial information projects total revenue to grow from $8 million in Q4 2025 to a peak of $6.849 billion in 2042, with EBIT and unlevered free cash flow also showing significant growth over this period, reflecting the potential commercialization of its pipeline drug candidates petosemtamab and MCLA-129. However, these projections are inherently uncertain and subject to various risks, including the success and timing of clinical development, regulatory approvals, and market acceptance. The transaction with Genmab offers a certain, immediate value in contrast to these long-term, uncertain prospects.

Management Comments

• The Merus Board unanimously determined that the Transaction Agreement, the Offer, the Back-End Transactions and the other Transactions to be consummated by Merus are in the best interests of Merus and the sustainable success of its business, having considered the interests of its shareholders, employees and other relevant stakeholders.
• The Merus Board believed this certainty of value and potential enhanced capacity for execution was compelling compared to the long-term value creation potential of Merus business, taking into account the risks of remaining independent and pursuing Merus current business and financial plans.
• The Merus Board's belief that it had obtained Genmab's best and final offer, and that a number of other strategic parties who had previously expressed a potential interest in acquiring or otherwise participating in a collaboration opportunity with Merus, including Party A, Party B, Party C and Party D, had not expressed the desire or ability to participate in the strategic process at this time, or had not proposed a higher valuation or value-accretive transaction comparative to the final offer of $97.00 per Common Share made by Genmab.

Industry Context

The acquisition of Merus by Genmab reflects a trend of consolidation in the biopharmaceutical industry, particularly in oncology, where larger players seek to acquire innovative pipeline assets and technology platforms (like Merus's Biclonics and Triclonics) to address unmet medical needs and improve treatment outcomes for cancer patients. The transaction provides Merus with enhanced financial and operational resources from Genmab, potentially accelerating the development and commercialization of its multispecific antibody therapeutics, such as petosemtamab and MCLA-129, in a highly competitive and evolving regulatory landscape. This move by Genmab strengthens its position in the oncology market by integrating Merus's specialized antibody therapeutics and technology.

Comparison to Industry Standards

• The offer price of $97.00 per share represents a 41% premium to Merus's closing price on September 26, 2025, and a 50% premium to its 60-day volume-weighted average price, which are generally considered attractive premiums in biopharma M&A transactions.
• Jefferies LLC's financial analysis, including a selected public companies analysis (e.g., Arcellx, Inc., Arcus Biosciences, Inc., Celcuity Inc., CG Oncology, Inc., IDEAYA Biosciences, Inc., ImmunityBio, Inc., Nuvalent, Inc., Revolution Medicines, Inc., Summit Therapeutics Inc.) and a selected precedent transactions analysis (e.g., Fusion Pharmaceuticals Inc./AstraZeneca PLC, Ambrx Biopharma, Inc./Johnson & Johnson Inc., RayzeBio, Inc./Bristol Myers Squibb Company), supported the fairness of the offer consideration from a financial point of view.
• The discounted cash flow analysis indicated an approximate implied equity value reference range per common share of $89.90 to $109.45, with the $97.00 offer falling within this range, suggesting a fair valuation based on Merus's projected standalone performance.
• Publicly available share price targets for Merus common shares from selected research analysts ranged from $67.00 to $112.00, with a median of $93.50, indicating that the offer price is at the higher end of pre-announcement analyst expectations.
• The termination fees ($240 million for Merus and $416 million for Genmab) are stated to be reasonable relative to termination fees typically seen in transactions of a similar size in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The risk of litigation is a general factor considered by the Merus Board.
• Actions brought or threatened by Merus shareholders alleging breach of fiduciary duty or violations of securities laws in connection with the Schedule 14D-9 and EGM Materials.
• Merus will control any action brought by its shareholders or other persons against Merus or its directors, officers, or representatives arising out of or relating to the Transaction Agreement or the Transactions.

Related Party Transactions

• Except for employment agreements or other compensation arrangements in the ordinary course of business, there are no Contracts between Merus or its subsidiaries and any of Merus's affiliates that would require disclosure under Item 404 of Regulation S-K.
• Merus entered into a Foundation Support Agreement with Stichting Continuteit Merus (the Protection Foundation), which is also party to a Call Option Agreement. Under the Support Agreement, the Protection Foundation agreed not to exercise its call option and to terminate the Call Option Agreement upon closing, supporting the Transactions.

Stakeholder Impact

• Shareholders: Will receive $97.00 per share in cash, representing a significant premium. Non-tendering minority shareholders may face Dutch dividend withholding tax in certain back-end scenarios and will hold illiquid shares in a private entity.
• Employees: Continuing employees will receive comparable compensation and benefits for one year post-closing. Executive officers have accelerated vesting of options and potential severance/tax reimbursements. A cash-based retention program up to $10 million is permitted.
• Directors/Officers: Current directors and executive officers have financial interests (accelerated option vesting, severance, tax reimbursements) different from general shareholders. Indemnification and D&O insurance will continue for six years.
• Protection Foundation: Agreed not to exercise its call option and to terminate its agreement, supporting the transaction.
• Customers/Suppliers/Partners: The Merus Board considered the interests of all relevant stakeholders, including employees, in determining the transaction to be in the best interests of the company and its sustainable success.

Next Steps

• Purchaser will commence a subsequent offering period for at least ten business days after the initial offer expires.
• If conditions are met, Merus will become an indirect wholly-owned subsidiary of Genmab through Back-End Transactions (statutory merger or compulsory acquisition).
• Merus common shares will be delisted from Nasdaq and deregistered under the Exchange Act.
• Merus will initiate consultation procedures with its works council, and Genmab B.V. with its works council, regarding the Employee Consultation Transactions.
• Genmab and Merus will cooperate to obtain required antitrust approvals (HSR Act, UK Competition and Markets Authority).
• Merus will hold an Extraordinary General Meeting (EGM) on December 9, 2025, to vote on Back-End Transaction Resolutions, Discharge Resolutions, and Governance Resolutions.
• Genmab will obtain and prepay tail D&O insurance policies for Merus's current and former directors and officers for six years post-closing.
• Genmab will cause the Company Board members resigning at closing to be fully and finally discharged at the first general meeting after closing.
• The Protection Foundation and its board members will take all actions necessary to effect the dissolution and liquidation of the Foundation following the Closing.

Key Dates

Recommendation

The unanimous recommendation by the Merus Board, coupled with a substantial 41% premium over the recent closing price and 50% over the 60-day volume-weighted average price, makes this an attractive all-cash offer. The committed financing from Genmab further de-risks the transaction. While there are tax implications for non-tendering shareholders and the loss of future standalone upside, the immediate, certain cash value at a premium is compelling, especially given the inherent risks of a clinical-stage biopharmaceutical company. Shareholders should tender their shares.

Keywords

Merus N.V., Genmab A/S, Tender Offer, Acquisition, Biotechnology, Oncology, MRUS, SEC Filing, M&A, Shareholder Vote, Back-End Transactions, Stock Options, Delisting, Corporate Governance, Financial Advisory, Jefferies LLC, Petosemtamab, MCLA-129